Early rhythm control therapy initiated within eight weeks of admission for acute ischemic stroke in patients with atrial fibrillation was associated with a reduced hazard of recurrent ischemic stroke or systemic embolism by nearly half, according to data published in Neurology.
The nationwide retrospective cohort study, utilizing the DeSC-IQVIA integrated claims database in Japan, examined 14,355 adults hospitalized for acute ischemic stroke with atrial fibrillation present at admission between 2014 and 2025. Researchers classified patients at an eight-week landmark into those receiving early rhythm control—defined as antiarrhythmic drugs, catheter ablation, or electrical cardioversion—and those receiving usual care.
Early Rhythm Control Lowers Recurrent Stroke Risk
- New Prevention Window: Beyond standard blood-thinning anticoagulants, early rhythm control therapy within eight weeks of a stroke can serve as an additional protective strategy.
- Measurable Risk Reduction: Patients who received early rhythm treatment experienced an 8.0% weighted five-year cumulative incidence of recurrent stroke or systemic embolism, compared to 13.8% in the usual care group.
- Survival Benefit: The intervention was also linked to lower all-cause mortality, dropping to a 24% weighted five-year cumulative incidence from 40% in the control cohort.
Kyoto University Investigation Highlights Timing and Mortality Outcomes
Led by Shuhei Egashira of the Graduate School of Medicine at Kyoto University, the research team evaluated early rhythm control therapy compared with usual care after acute ischemic stroke in patients with atrial fibrillation. The median age of the cohort was 83 years, with 48.3% women, reflecting a highly aged demographic.
Out of the total study population, 268 patients received early rhythm control therapy within the initial eight-week window, while 14,087 patients received usual care without rhythm intervention. The primary endpoint tracked hospitalizations for recurrent ischemic stroke or systemic embolism. The resulting hazard ratio stood at 0.56, with a 95% confidence interval ranging from 0.32 to 0.97, yielding a risk difference of -5.9 percentage points.
| Outcome Measure | Early Rhythm Control Group | Usual Care Group | Statistical Impact (HR / Risk Difference) |
|---|---|---|---|
| Recurrent Stroke or Systemic Embolism (5-Yr) | 8.0% | 13.8% | HR 0.56 (CI, 0.32–0.97) |
| All-Cause Mortality (5-Yr) | 24% | 40% | HR 0.72 (CI, 0.53–0.97) |
| Heart Failure Hospitalization | Not linked | Not linked | Not linked |
| Major Bleeding Events | Not linked | Not linked | Not linked |
Corresponding investigator Yuichi Imanaka, MD, MPH, PhD, emphasized the clinical implications of the findings in a press release. People who have an ischemic stroke are prescribed anticoagulants, medications that stop the blood from clotting easily, to prevent a second stroke. Our study suggests that early rhythm control may serve as another prevention strategy, with flexible timing of initiation, within eight weeks of stroke,
Imanaka stated.
Secondary endpoints confirmed that early rhythm control did not increase the incidence of major bleeding or heart failure hospitalizations. Subgroup analyses revealed that the risk reduction was even more pronounced among patients lacking intracranial or extracranial artery stenosis, yielding a hazard ratio of 0.36.
Small Participant Group Limits Study Precision
Despite the significant statistical findings, the study carries notable limitations. The early rhythm control group was relatively small at 268 participants, which limits statistical precision for long-term outcomes. Claims data lacked granular clinical variables such as stroke severity, functional status, imaging findings, echocardiographic parameters, and precise atrial fibrillation burden.
Researchers noted that treatment crossover and time-dependent confounding after the landmark period were not fully addressed, and residual confounding from unmeasured factors cannot be completely excluded. Coding errors and misclassification of atrial fibrillation types also remain possible. Finally, because the cohort consisted predominantly of older Japanese adults, the generalizability of these findings to broader international populations requires further investigation.
The underlying research was funded by the Japan Society for the Promotion of Science. Disclosure information for the study investigators is available in the original publication.
Clinical Outlook on Post-Stroke Atrial Fibrillation Management
The October publication in Neurology found that early rhythm control therapy initiated within eight weeks of admission was associated with lower risks of recurrent ischemic stroke or systemic embolism and all-cause mortality.
References
- Egashira, S., et al. Published online October 21 in Neurology.
- DeSC-IQVIA Integrated Claims Database, Japan (2014–2025).
Always seek the advice of your physician or other qualified health provider with any questions regarding a medical condition.
